People · Operator
Named in public records as an officer, director or promoter · active 2009–2015 · Biotechnology, Other Technology, Other Health Care, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Fate Therapeutics Inc | — | Biotechnology | Series C | $241.3M | $2.0B | 2009 |
| Novomer Inc | — | Other Technology | Series B | $33.0M | $456.8M | 2009 |
| Groove Biopharma Corp | — | Other Health Care | Series A | $8.4M | $90.8M | 2010 |
| Allozyne Inc | — | Biotechnology | Seed | $8.2M | $108.9M | 2012 |
| Acylin Therapeutics, Inc. | — | Biotechnology | Seed | $4.0M | $88.8M | 2010 |
| Oncofactor Corp | — | Biotechnology | Seed | $3.1M | $44.4M | 2011 |
| XORI Corp | — | Biotechnology | Seed | $2.1M | $93.4M | 2009 |
| Matrix Genetics, LLC | — | Other | Seed | $1.6M | $29.7M | 2015 |
Carl Weissman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Carl Weissman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Thong Le | 4 | 12 |
| Chad Waite | 4 | 11 |
| Lindsay Rayle | 4 | 7 |
| Steven Gillis | 3 | 23 |
| David Schubert | 3 | 6 |
| Steve Gillis | 2 | 13 |
| Lee Babiss | 2 | 5 |
| Janis Naeve | 2 | 3 |
| Robert Nelsen | 1 | 22 |
| Bryan Roberts | 1 | 18 |
| Michael Lee | 1 | 15 |
| Amir Nashat | 1 | 14 |
| Robert Epstein | 1 | 8 |
| Andrew Williamson | 1 | 6 |
| Bryan E. Roberts | 1 | 6 |
| Brian Atwood | 1 | 6 |
| FRED ESHELMAN | 1 | 5 |
| PAUL Grayson | 1 | 5 |
| Robert T. Nelsen | 1 | 5 |
| Michael Steinmetz | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.